Integrative analysis identifies two molecular and clinical subsets in Luminal B breast cancer

Simple item page
dc.citation.issue9
dc.citation.volume26
dc.contributor.authorWang H
dc.contributor.authorLiu B
dc.contributor.authorLong J
dc.contributor.authorYu J
dc.contributor.authorJi X
dc.contributor.authorLi J
dc.contributor.authorZhu N
dc.contributor.authorZhuang X
dc.contributor.authorLi L
dc.contributor.authorChen Y
dc.contributor.authorLiu Z
dc.contributor.authorWang S
dc.contributor.authorZhao S
dc.coverage.spatialUnited States
dc.date.accessioned2024-10-02T20:15:22Z
dc.date.available2024-10-02T20:15:22Z
dc.date.issued2023-09-15
dc.description.abstractComprehensive multiplatform analysis of Luminal B breast cancer (LBBC) specimens identifies two molecularly distinct, clinically relevant subtypes: Cluster A associated with cell cycle and metabolic signaling and Cluster B with predominant epithelial mesenchymal transition (EMT) and immune response pathways. Whole-exome sequencing identified significantly mutated genes including TP53, PIK3CA, ERBB2, and GATA3 with recurrent somatic mutations. Alterations in DNA methylation or transcriptomic regulation in genes (FN1, ESR1, CCND1, and YAP1) result in tumor microenvironment reprogramming. Integrated analysis revealed enriched biological pathways and unexplored druggable targets (cancer-testis antigens, metabolic enzymes, kinases, and transcription regulators). A systematic comparison between mRNA and protein displayed emerging expression patterns of key therapeutic targets (CD274, YAP1, AKT1, and CDH1). A potential ceRNA network was developed with a significantly different prognosis between the two subtypes. This integrated analysis reveals a complex molecular landscape of LBBC and provides the utility of targets and signaling pathways for precision medicine.
dc.description.confidentialfalse
dc.format.pagination107466-
dc.identifier.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/37636034
dc.identifier.citationWang H, Liu B, Long J, Yu J, Ji X, Li J, Zhu N, Zhuang X, Li L, Chen Y, Liu Z, Wang S, Zhao S. (2023). Integrative analysis identifies two molecular and clinical subsets in Luminal B breast cancer.. iScience. 26. 9. (pp. 107466-).
dc.identifier.doi10.1016/j.isci.2023.107466
dc.identifier.eissn2589-0042
dc.identifier.elements-typejournal-article
dc.identifier.issn2589-0042
dc.identifier.number107466
dc.identifier.piiS2589-0042(23)01543-2
dc.identifier.urihttps://mro.massey.ac.nz/handle/10179/71575
dc.languageeng
dc.publisherElsevier Inc
dc.publisher.urihttps://www.sciencedirect.com/science/article/pii/S2589004223015432
dc.relation.isPartOfiScience
dc.rights(c) The author/sen
dc.rights.licenseCC BY-NC-NDen
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/en
dc.subjectBioinformatics
dc.subjectCancer systems biology
dc.subjectMicroenvironment
dc.titleIntegrative analysis identifies two molecular and clinical subsets in Luminal B breast cancer
dc.typeJournal article
pubs.elements-id480010
pubs.organisational-groupOther
Files
Original bundle
Now showing 1 - 5 of 10
Thumbnail Image
Name:
Published version.pdf
Size:
7.09 MB
Format:
Adobe Portable Document Format
Description:
480010 PDF.pdf
Download
Thumbnail Image
Name:
Evidence 1
Size:
20.3 KB
Format:
Microsoft Excel
Description:
1-s2.0-S2589004223015432-mmc9.xlsx
Download
Thumbnail Image
Name:
Evidence 2
Size:
10.08 KB
Format:
Microsoft Excel
Description:
1-s2.0-S2589004223015432-mmc2.xlsx
Download
Thumbnail Image
Name:
Evidence 3
Size:
9.7 KB
Format:
Microsoft Excel
Description:
1-s2.0-S2589004223015432-mmc3.xlsx
Download
Thumbnail Image
Name:
Evidence 4
Size:
12.13 KB
Format:
Microsoft Excel
Description:
1-s2.0-S2589004223015432-mmc4.xlsx
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
9.22 KB
Format:
Plain Text
Description:
Download
Collections
Journal Articles